Clinical Trial

Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and tolerability of mezigdomide in combination with ziftomenib in adolescent and adult participants with either KMT2A-rearranged (KMT2A-r) or NPM1-mutant relapsed or refractory acute myeloid leukemia (AML).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-12.
Trial Details
NCT Number NCT07355335
Lead Sponsor Massachusetts General Hospital
Collaborators: Kura Oncology, Inc., Bristol-Myers Squibb
Conditions KMT2A-rearranged, NPM1-mutant Refractory or Relapsed AML
Enrollment 24 participants
Start Date 2026-07-09
Primary Completion 2027-07-01 (estimated)
Study Completion 2028-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-22